AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05357846 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative radiotherapy
Description: External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
Study NCT05662787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Description: Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in above the knee lesions prior to full balloon dilatation at low pressures
Study NCT06028243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Information stage
Description: The researchers provided the intervention group participants with online training in healthy living awareness to prevent osteoporosis (400 minutes and two days). They held the training at all participants' convenience outside the class hours. The training consisted of four sections: (1) osteoporosis and diagnosis-treatment methods, (2) current approaches to the prevention of osteoporosis, (3) osteoporosis and nutrition, and (4) osteoporosis and physical exercise. The researchers employed interactive teaching methods and consulted three experts to prepare PowerPoint presentations. At the end of the training, the researchers taught the intervention group participants how to fill out the healthy life diary, such as calculating daily calcium intake. The researchers texted the intervention group participants all training videos on WhatsApp to allow them to watch them again.
Study NCT06028243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Motivation stage
Description: The researchers regularly texted (WhatsApp) spot and reminder notifications concerning the prevention of osteoporosis. They asked them to assess the health behaviors they recorded in their diaries every week (daily calcium intake, weekly exercise duration, etc.) and the problems they experienced during the process. The researchers provided individual counseling to the participants by telephone (combating smoking, exercise barriers, food exchange for calcium sources, etc.)
Study NCT06028243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Behavior skills stage
Description: The target behavior skills were improved self-efficacy in doing weight-bearing exercises, taking calcium, and engaging in physical activity.
Study NCT05617729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline applied via swab
Description: sterile saline applied via swab
Study NCT05617729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine based gel
Description: gel applied via swab
Study NCT05316272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised bone-loading exercise on 3 days per week for 36 weeks
Study NCT05316272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA in pill form 50 milligrams taken daily for 36 weeks
Study NCT05452174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
Study NCT04996004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontorpacept (TTI-621)
Description: Ontorpacept (TTI-621) will be administered by intravenous infusion.
Study NCT04996004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
Study NCT05815550 — intervention group
Intervention type: DRUG
Intervention: PPI
Description: Use of PPI defined as PPI mentioned in the safety report
Study NCT04300751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Active alcohol or placebo, administered orally
Study NCT04300751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Active opioid agonist or placebo, administered orally
Study NCT05751278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651
Description: ERBE 1.1mm flexible single-use cryoprobe with oversheath
Study NCT05751278 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Jaw 4 Pulmonary Biopsy Forceps
Description: Radial Jaw 4 Pulmonary Biopsy Forceps Standard Capacity for 2mm endoscope
Study NCT05846646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
Study NCT05846646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune checkpoint inhibitor
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label
Study NCT05846646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label
Study NCT05846646 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PULSAR
Description: 1st day of Cycles 1, 2 and 3.
Study NCT05846646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PULSAR
Description: 1st day of Cycles 1, 2 and 3.
Study NCT05357846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Description: External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
Study NCT05357846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
Study NCT06133153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THIODERM ELATE
Description: Thiomer-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
Study NCT06133153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Ultra 3
Description: BDDE-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
Study NCT04224974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial
Study NCT04224974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EASE-psy
Description: All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT).~-EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms.
Study NCT05357846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
Study NCT05357846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
Study NCT05357846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
Study NCT05357846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophagectomy
Description: McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
Study NCT05357846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagectomy
Description: McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
Study NCT04844619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg/ml KDR2-2 suspension eyedrop
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.
Study NCT04844619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16mg/ml KDR2-2 suspension eyedrop
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.
Study NCT06271876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances
Study NCT06271876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances
Study NCT05860582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]GB491
Description: A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.
Study NCT04905459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ARDA software application
Description: Subject images will be sent to the investigational ARDA software
Study NCT05526651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: true electroacupuncture
Description: the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
Study NCT05526651 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation
Study NCT05334316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered intravenously or orally based on daily CRP values and CRP corticosteriod dosing algorithm
Study NCT04873427 — intervention group
Intervention type: GENETIC
Intervention: clonal heterogeneity evaluation
Description: Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
Study NCT06264128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPAP
Description: TPAP is a form of CPAP therapy where the therapy pressure is reduced from the beginning of inhalation through mid or later exhalation. The CPAP therapy pressure is only present at the end of the expiratory phase.
Study NCT06264128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP is a standard formal at home therapy for obstructive sleep apnea where a device attached via a facemask applies a constant pressure to a patient's lungs during sleep. It is the reference standard in this study.
Study NCT05611827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin LipoMicel (250 mg)
Description: Quercetin LipoMicel® soft-gels. Total dose of 250 mg of quercetin
Study NCT05611827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin LipoMicel (500 mg)
Description: Quercetin LipoMicel® soft-gels. Total dose of 500 mg of quercetin
Study NCT05611827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin LipoMicel (1000 mg)
Description: Quercetin LipoMicel® soft-gels. Total dose of 1000 mg of quercetin
Study NCT05611827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular/standard Quercetin (500 mg)
Description: Total dose of 500 mg of quercetin
Study NCT06367088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Patients were assigned to receive 10 mg/kg cadonilimab intravenously Q3W in combination with chemotherapy. The chemotherapy regimen is chosen by the physician.
Study NCT04893343 — intervention group
Intervention type: OTHER
Intervention: Antibiotic treatment
Description: Antibiotic treatment
Study NCT04893343 — intervention group
Intervention type: OTHER
Intervention: No antibiotic treatment
Description: No antibiotic treatment
Study NCT06002932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: planed 2-stent strategy
Description: Procedure: planed 2-stent strategy
Study NCT06002932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: provisional 1-stent plus DEB strategy
Description: Procedure: provisional 1-stent plus DEB strategy
Study NCT06050616 — intervention group
Intervention type: OTHER
Intervention: MRI scans
Description: Neuroimaging data will be collected with magnetic resonance imaging (MRI).~Structural neuroimaging will include T1 and T2-weighted scans, and diffusion tensor imaging (DTI).~Functional neuroimaging will include scans under the stop-signal task, monetary incentive delay task, and emotional faces task, and resting state.
Study NCT06050616 — intervention group
Intervention type: OTHER
Intervention: Psychological measures
Description: Cognitive performance assessed by Wechsler Adult Intelligence Scale 4th Edition.~Personalities assessed by NEO Five-Factor Inventory (NEO-FFI), Substance Use Risk Profile Scale (SURPS), and Temperament and Character Inventory (TCI).~Other psychological assessments include Interpersonal Reactivity Index, Perceived Stress Scale, Kirby Monetary Choice Questionnaire, Passive Avoidance Learning Paradigm, and Stimulus-response compatibility.
Study NCT06050616 — intervention group
Intervention type: OTHER
Intervention: Life experiences
Description: Self-report questionnaires on experiences of bullying and trauma.
Study NCT06050616 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood and urine samples
Description: Blood and urine samples will be collected but will not undergo analysis in this study. Instead, these samples will be stored in a biobank for potential analysis in future research.
Study NCT06050616 — intervention group
Intervention type: OTHER
Intervention: Mental health symptoms
Description: Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview.
Study NCT05071820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health U mobile application
Description: Health U mobile application delivers daily microlearning modules and the health coach interactions within the Health U application
Study NCT05071820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National Diabetes Prevention Program
Description: CDC recognized National DPP that follows a set curriculum with modules delivered over 12 months
Study NCT06064968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent bladder catheterization
Description: Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
Study NCT06064968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent bladder catheterization
Description: Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
Study NCT06240598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Look Laparoscopy
Description: Second Look Laparoscopy (SLL)
Study NCT04531826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5-strand hamstring graft preparation
Description: Five-strand hamstring graft preparation
Study NCT04531826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5-strand hamstring graft preparation
Description: Five-strand hamstring graft preparation
Study NCT04440501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Goggles to provide education a regarding the gluten free diet.
Description: To watch and participate in a virtual reality educational experience regarding the gluten free diet.
Study NCT04746638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: whole body study and SPECT with 99mTc-RM26
Description: One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study NCT04789408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT04789408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT04789408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KITE-222
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Study NCT05437601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astaxanthin Oral Capsule
Description: 12 mg oral astaxanthin daily for 8 weeks
Study NCT05437601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo identical to astaxanthin
Study NCT05183789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of serum levels of IL-6 and IL-8
Description: Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).
Study NCT05618808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN9933
Description: Participants will receive a single dose of REGN9933 by IV infusion
Study NCT05618808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
Study NCT05618808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixiban
Description: Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
Study NCT05138744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral activation using virtual reality
Description: The investigators will encourage behavioral activation (increase in the number and time of conducted activities) situating the person in motivating situations using virtual reality
Study NCT05324683 — intervention group
Intervention type: OTHER
Intervention: No intervention planned
Description: No intervention planned; study is observational
Study NCT05850728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-ART
Description: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
Study NCT06317467 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Four blood samples will be collected, in conjunction with the collection of samples already programmed for assistance during pregnancy: blood sampling for the B-test (within the 13th week of gestation), at the blood test centre of the Institute for Maternal and Child Health, IRCCS Burlo Garofolo; blood sampling for toxoplasmosis or blood sugar level, upon execution of the morphological ultrasound scanning (around the 20th and 34th weeks of gestation), at the blood test centre of the Institute for Maternal and Child Health, IRCCS Burlo Garofolo, as well. Finally, 40 days after delivery, during routine gynaecological control after the puerperium.
Study NCT06317467 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: For patient of group 2, the blood sample will be collected at the time of the diagnosis of PE and 40-50 days after delivery in Obstetrics and Gynaecology Department of the institute or in Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Study NCT05378477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X92001752
Description: The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
Study NCT05378477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RID Super Max Solution
Description: RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
Study NCT05378477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nix Crème
Description: Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.
Study NCT05378477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pouxit Végétal
Description: Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.